Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

(May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading


Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

(May 7, 2019)

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About... Continue Reading


Darolutamide Delays Prostate Cancer Progression in Men with Resistant Prostate Cancer

(March 14, 2019)

Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT... Continue Reading


Adjuvant Taxotere Doesn’t Improve Outcomes in Early Stage High Risk Prostate Cancer

(February 11, 2019)

Patients with high-risk, non-metastatic prostate cancer saw no survival advantage and no delay in metastases with the addition of adjuvant docetaxel to androgen deprivation therapy (ADT), according to the results of a pivotal clinical randomized trial... Continue Reading


Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer

(December 31, 2018)

177Lu-PSMA-617 is a member of a new class of drugs that deliver radiation directly to tumor cells to obliterate them. These targeted radiation treatments consist of a radioactive isotope attached to a molecule that specifically targets tumor cells. In... Continue Reading


FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

(July 17, 2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading


Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer

(May 1, 2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading


Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer?

(February 22, 2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that... Continue Reading


Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer

(February 19, 2018)

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Erleada... Continue Reading


Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation

(February 14, 2018)

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif. ... Continue Reading


Latest Prostate Cancer News By Stage


Early Stage I-II (A-B) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Early Stage I-II (A-B) Prostate Cancer

Locally Advanced Stage III (C) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Locally Advanced Stage III (C) Prostate Cancer

Metastatic Stage IV (D) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Metastatic Stage IV (D) Prostate Cancer

Refactory/Recurrent Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Refactory/Recurrent Prostate Cancer

Screening/Prevention Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Prostate Cancer